aThe George Institute for Global Health, University of New South Wales
bSydney Medical School, University of Sydney, Sydney
cDepartment of Physiology, Royal Melbourne Hospital, University of Melbourne, Victoria, Australia
dInstituto Auxologico Italiano, University of Milan-Bicocca, Milan, Italy
eDepartment of Endocrinology, Hopital Bichat-Claude Bernard, University of Paris, Paris, France
fImperial Clinical Trials Unit, Imperial College London, UK
gBordeaux Population Health Research Center, University of Bordeaux, France
hUniversity College London, NIHR University College London, Hospitals Biomedical Research Centre, London, UK
iSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
jDepartment of Epidemiology and Biostatistics, Imperial College, London, UK
kDepartment of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA
Correspondence to John Chalmers, MD, PhD, The George Institute for Global Health, University of Sydney, Level 10, King George V Building, PO Box M201, Camperdown, NSW 2050, Australia. Tel: +61 2 9993 4587; fax: +61 2 9993 4588; e-mail: [email protected]
Abbreviations: ADVANCE, The Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; BP, blood pressure; CI, confidence intervals; PAPA-CAD, Perindopril plus Amlodipine in PAtients with Coronary Artery Disease; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; SD, standard deviation; TIPS, The Indian Polycap Study
Received 21 December, 2020
Revised 15 February, 2021
Accepted 13 March, 2021
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).
